pubmed.ncbi.nlm.nih.gov

A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies - PubMed

  • ️Thu Jan 01 2015

A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies

Maksim Mamonkin et al. Blood. 2015.

Abstract

Options for targeted therapy of T-cell malignancies remain scarce. Recent clinical trials demonstrated that chimeric antigen receptors (CARs) can effectively redirect T lymphocytes to eradicate lymphoid malignancies of B-cell origin. However, T-lineage neoplasms remain a more challenging task for CAR T cells due to shared expression of most targetable surface antigens between normal and malignant T cells, potentially leading to fratricide of CAR T cells or profound immunodeficiency. Here, we report that T cells transduced with a CAR targeting CD5, a common surface marker of normal and neoplastic T cells, undergo only limited fratricide and can be expanded long-term ex vivo. These CD5 CAR T cells effectively eliminate malignant T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoma lines in vitro and significantly inhibit disease progression in xenograft mouse models of T-ALL. These data support the therapeutic potential of CD5 CAR in patients with T-cell neoplasms.

© 2015 by The American Society of Hematology.

PubMed Disclaimer

Figures

Figure 1
Figure 1

CD5 CAR T cells expand and downregulate CD5. (A) Schematic structure of CD5 CAR and transduction efficiency of primary activated T cells. (B) Expansion of activated T cells transduced with either Ctrl CAR or CD5 CAR. Data denote mean ± SD from 4 donors. (C) Surface expression of CD5 on NT T cells or T cells transduced with Ctrl CAR or CD5 CAR at 7 days post-activation. (D) Relative expression of CD5 messenger RNA in NT activated T cells or T cells transduced with CD5 CAR at 7 days post-stimulation. Ctrl CAR, control CAR; NT, nontransduced.

Figure 2
Figure 2

CD5 CAR T cells produce limited fratricide and spare VSTs. (A) Autologous GFP+ T cells were mixed with T cells transduced with Ctrl CAR, truncated CD5 CAR (ΔCD5 CAR, without intracellular signaling domains), or full length CD5 CAR at 1:2 E:T ratio and cocultured for 7 days. Numbers in dot plots denote cell counts of gated GFP+ autologous T cells per well at indicated time points (left). Graph (right) summarizes data from 4 donors ± SD. (B) Phenotype of activated T cells 10 days after transduction with Ctrl CAR or CD5 CAR. Naïve T cells (TNAIVE, CD45RA+ CCR7+), central memory (TCM, CD45RA− CCR7+), effector and effector-memory (TEFF/TEM, CD45RA− CCR7−), and TEMRA (CD45RA+ CCR7−) subsets are shown on representative dot plots with gating strategy (left) and as mean data from 3 donors (right). (C) Phenotype of autologous GFP+ T cells after coculture with Ctrl CAR- or CD5 CAR-transduced T cells for 24 hours. Data shown as mean average from 3 donors. (D) Autologous GFP+ T cells were cocultured with Ctrl CAR T or CD5 CAR T cells for 72 hours and purified by cell sorting. Frequency of T cells specific for cytomegalovirus, Epstein-Barr virus, and adenovirus among sorted cells was measured by IFN-γ ELISPOT.

Figure 3
Figure 3

CD5 CAR T cells eliminate malignant T cells in vitro. (A) Cytotoxicity of CD19 CAR- and CD5 CAR-transduced T cells against T-ALL and T-lymphoma cell lines was assessed in a 5-hour Cr release assay. CD19+CD5− Raji cells (bottom right panel) were used as a negative control for CD5 CAR and positive control for CD19 CAR T cells. (B) Panel i: production of IFN-γ and TNF-α by CD4+ (top) and CD8+ (bottom) T cells transduced with CD19 CAR or CD5 CAR was measured by intracellular cytokine staining. Panel ii: bar graphs show mean ± SD from 3 donors. (C) Long-term coculture of CAR T cells with GFP+ target cell lines Jurkat, CCRF, and MOLT4 at an initial E:T ratio 1:4. Numbers in dot plots denote percentage of target GFP+ cells at indicated time points. (D) Sequential killing of GFP+ Jurkat cells by CD5 CAR T cells. Graph indicates number of target Jurkat cells per well at the beginning and the end of each cycle of cell killing. Data from 3 individual donors are shown.

Figure 4
Figure 4

Multiple mechanisms contribute to resistance to fratricide. (A) Inhibition of cytotoxicity of CD5 CAR T cells against autologous T cells and Jurkat cells by blocking either FasL (brefeldin A + aFasL), perforin (CMA + EGTA), or both pathways. Cell death was measured by Annexin V after 2 hours of coculture. (B) Expression of PI-9 protein in CD5 CAR T cells and malignant T-cell lines was measured by intracellular staining and flow cytometry (left). Bar graphs show MFI of PI-9 (right). (C) Expression of cathepsin B transcript in CD5 CAR T cells and target cell lines was measured by quantitative polymerase chain reaction. (D) Levels of Bcl-2 transcript in CD5 CAR T cells and target cell lines. (E) Protein expression of Bcl-2 was measured by intracellular staining and flow cytometry. (F) Bid expression in CD5 CAR T cells and target cell lines was measured by quantitative polymerase chain reaction. Error bars denote SD for 3 different T cell donors. MFI, mean fluorescence intensity.

Figure 5
Figure 5

CD5 CAR T cells recognize and kill primary T-ALL cells. (A) Production of IFN-g upon coculture with different primary T-ALL samples was assessed by intracellular cytokine staining. Numbers indicate percent or CAR+ T cells positive for IFN-g. (B) Production of IFN-g (left), TNFa (middle), and expression of CD107a (right) by CD5 CAR T cells upon mixing with thawed T-ALL blasts from 2 patients (T-ALL #295 and #315). Bar graphs depict frequency of cytokine-producing CD4+ and CD8+ T cells as average ± SEM from 4 donors. (C) Cytotoxicity of CD5 CAR T cells against fresh primary T-ALL blasts isolated from peripheral blood mononuclear cells of a T-ALL patient #394 was measured in a 5-hour Cr release assay. (D) Protein expression of PI-9 and (E) Bcl-2 in T-ALL blasts from donor #394 was measured by intracellular staining and flow cytometry. Expression histogram in Jurkat cells is shown with a dotted line (left). Bar graphs depict corresponding MFI compared with CD5 CAR T cells (mean ± SD from 3 donors) and Jurkat T-ALL cell line (right).

Figure 6
Figure 6

CD5 CAR T cells control progression of T-ALL in xenograft mouse models. (A) Jurkat-FFluc cells (3 × 106 per mouse) were IV injected followed by IV injection of CAR T cells (10 × 106 per mouse) on days 3 and 6 postimplantation. Tumor burden was assessed by IVIS imaging at indicated time points. (B) Kaplan–Meier survival curve; mice were euthanized after developing hind limb paralysis. (C) Eradication of systemic disease by CD5 CAR T cells. Mice were engrafted with Jurkat-FFluc cells, which established systemic disease by day 6. (D) Total luminescence from Jurkat cells recorded on day 6 (prior to CAR T-cell injection) and day 12. (E) Kaplan–Meier survival curve for eradication of systemic disease. (F) CCRF-CEM–FFluc cells (1 × 106 per mouse) were IV injected followed by IV injection of CAR T cells (10 × 106 per mouse) on day 3 and 6 post-implantation. Tumor burden was assessed by IVIS imaging at indicated time points. (G) Relative frequency CCRF-GFP in peripheral blood of mice on day 18 post-engraftment is shown on representative dot plots. (H) Kaplan–Meier survival curve for the CCRF model. P values are shown for each experiment.

Comment in

Similar articles

Cited by

References

    1. Kantarjian HM, Thomas D, Ravandi F, et al. Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission. Leuk Lymphoma. 2010;51(3):475–480. - PMC - PubMed
    1. Gökbuget N, Stanze D, Beck J, et al. German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012;120(10):2032–2041. - PubMed
    1. DeAngelo DJ, Yu D, Johnson JL, et al. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood. 2007;109(12):5136–5142. - PMC - PubMed
    1. Goldberg JM, Silverman LB, Levy DE, et al. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol. 2003;21(19):3616–3622. - PubMed
    1. Oudot C, Auclerc M-F, Levy V, et al. Prognostic factors for leukemic induction failure in children with acute lymphoblastic leukemia and outcome after salvage therapy: the FRALLE 93 study. J Clin Oncol. 2008;26(9):1496–1503. - PubMed

Publication types

MeSH terms

Substances